Everest Medicines Ltd
01952
Company Profile
Business description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.
Contact
1168 West Nanjing Road
16th Floor, CITIC Pacific Plaza
Jing’an District
Shanghai200041
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
722
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.80 | 1.50 | -0.02% |
| CAC 40 | 8,166.02 | 34.87 | 0.43% |
| DAX 40 | 24,953.34 | 20.26 | 0.08% |
| Dow JONES (US) | 49,055.99 | 356.41 | -0.72% |
| FTSE 100 | 10,222.41 | 73.56 | 0.72% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,700.33 | 98.98 | 0.42% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,493.71 | 17.17 | -0.13% |
| S&P 500 | 6,962.46 | 12.23 | 0.18% |
| S&P/ASX 200 | 8,975.10 | 0.80 | 0.01% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |